Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLRB NASDAQ:GOVX NASDAQ:IMAC NASDAQ:JBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$4.99+0.4%$7.92$4.36▼$94.50$9M0.51146,253 shs54,137 shsGOVXGeoVax Labs$0.76+4.0%$0.91$0.43▼$11.18$11.64M3.362.67 million shs983,499 shsIMACIMAC$0.06-10.4%$0.05$0.75▼$1.65$1.59M-0.88708,132 shs6,347 shsJBIOJade Biosciences$9.47-0.4%$0.00$6.57▼$105.00$7.99M1.06548,901 shs222,632 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences+0.40%+2.25%-54.49%-44.37%-93.65%GOVXGeoVax Labs+4.02%+12.48%-17.81%-8.38%-74.83%IMACIMAC-10.37%-12.39%+37.10%+32.56%-96.59%JBIOJade Biosciences-0.42%-3.56%+0.64%+946,999,900.00%+946,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLRBCellectar Biosciences2.2511 of 5 stars3.22.00.00.01.61.71.3GOVXGeoVax Labs2.2103 of 5 stars3.62.00.00.03.10.00.6IMACIMACN/AN/AN/AN/AN/AN/AN/AN/AJBIOJade Biosciences1.962 of 5 stars3.50.00.00.01.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLRBCellectar Biosciences 2.33Hold$375.007,415.03% UpsideGOVXGeoVax Labs 3.20Buy$8.881,067.76% UpsideIMACIMAC 0.00N/AN/AN/AJBIOJade Biosciences 3.00Buy$15.0058.39% UpsideCurrent Analyst Ratings BreakdownLatest IMAC, GOVX, JBIO, and CLRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.007/14/2025JBIOJade BiosciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.006/16/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/16/2025JBIOJade BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.005/14/2025CLRBCellectar BiosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/2/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $9.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLRBCellectar BiosciencesN/AN/AN/AN/A$8.98 per shareN/AGOVXGeoVax Labs$3.95M3.07N/AN/A$0.48 per share1.58IMACIMAC$15.22M0.10N/AN/A$0.69 per share0.09JBIOJade BiosciencesN/AN/AN/AN/A$92.88 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLRBCellectar Biosciences-$44.58M-$21.92N/AN/AN/AN/A-619.70%-158.04%8/13/2025 (Estimated)GOVXGeoVax Labs-$24.99M-$3.65N/AN/AN/A-438.20%-511.96%-286.58%8/5/2025 (Estimated)IMACIMAC-$10.54MN/A0.00N/AN/A-75.40%-52.17%-34.51%N/AJBIOJade Biosciences-$69.63M-$59.65N/A∞N/AN/A-60.01%-54.32%N/ALatest IMAC, GOVX, JBIO, and CLRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025CLRBCellectar Biosciences-$3.70N/AN/AN/AN/AN/A8/5/2025Q2 2025GOVXGeoVax Labs-$0.41N/AN/AN/A$0.37 millionN/A5/13/2025Q1 2025CLRBCellectar Biosciences-$5.10-$3.90+$1.20-$0.14N/AN/A5/1/2025Q1 2025GOVXGeoVax Labs-$0.59-$0.45+$0.14-$0.45$0.75 million$1.64 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLRBCellectar BiosciencesN/AN/AN/AN/AN/AGOVXGeoVax LabsN/AN/AN/AN/AN/AIMACIMACN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLRBCellectar BiosciencesN/A2.472.47GOVXGeoVax LabsN/A3.623.62IMACIMAC0.011.271.27JBIOJade BiosciencesN/A32.0132.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLRBCellectar Biosciences16.41%GOVXGeoVax Labs6.09%IMACIMAC24.27%JBIOJade BiosciencesN/AInsider OwnershipCompanyInsider OwnershipCLRBCellectar Biosciences5.04%GOVXGeoVax Labs1.20%IMACIMAC10.00%JBIOJade Biosciences24.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLRBCellectar Biosciences101.81 million1.72 millionOptionableGOVXGeoVax Labs1015.93 million15.73 millionNot OptionableIMACIMAC10626.49 million23.84 millionNot OptionableJBIOJade Biosciences20840,000632,000N/AIMAC, GOVX, JBIO, and CLRB HeadlinesRecent News About These CompaniesJade Biosciences (NASDAQ:JBIO) Coverage Initiated at Jefferies Financial GroupJuly 16 at 4:09 AM | americanbankingnews.comJBIO - Jade Biosciences Inc Financials | MorningstarJuly 11, 2025 | morningstar.comMJade Biosciences, Inc. to Participate in H.C. Wainwright and Stifel Biotech Investor ConferencesJuly 8, 2025 | quiverquant.comQJade Biosciences to Participate in Two Upcoming Investor ConferencesJuly 8, 2025 | globenewswire.comJade Biosciences Inc. Stock Grades | JBIO | Barron'sJuly 5, 2025 | barrons.comJade Biosciences Inc. Research & Ratings | JBIO | Barron'sJuly 5, 2025 | barrons.comJade Biosciences appoints Brad Dahms as new CFOJuly 2, 2025 | investing.comJade Biosciences, Inc. Appoints Brad Dahms as Chief Financial Officer to Drive Growth and Innovation - NasdaqJuly 2, 2025 | nasdaq.comJade Biosciences, Inc. Appoints Brad Dahms as Chief Financial Officer to Drive Growth and InnovationJuly 1, 2025 | quiverquant.comQJade Biosciences Appoints Brad Dahms as Chief Financial OfficerJuly 1, 2025 | globenewswire.com2 Small-Cap Stocks Under $10 to Buy With Big PotentialJune 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMAC, GOVX, JBIO, and CLRB Company DescriptionsCellectar Biosciences NASDAQ:CLRB$4.99 +0.02 (+0.40%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$5.07 +0.08 (+1.60%) As of 07/18/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.GeoVax Labs NASDAQ:GOVX$0.76 +0.03 (+4.02%) As of 07/18/2025 04:00 PM EasternGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.IMAC NASDAQ:IMAC$0.06 -0.01 (-10.44%) As of 07/17/2025IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides physical therapy and spinal decompression, and chiropractic manipulation. The company owns or manages 15 outpatient medical clinics in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.Jade Biosciences NASDAQ:JBIO$9.47 -0.04 (-0.42%) As of 07/18/2025 04:00 PM EasternAerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
